Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine

A Wilder-Smith; J Hombach; N Ferguson; M Selgelid; K O'Brien; K Vannice; A Barrett; E Ferdinand; S Flasche; M Guzman; HM Novaes; LC Ng; PG Smith; P Tharmaphornpilas; IK Yoon; A Cravioto; J Farrar; TM Nolan

Journal article

Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine

A Wilder-Smith, J Hombach, N Ferguson, M Selgelid, K O'Brien, K Vannice, A Barrett, E Ferdinand, S Flasche, M Guzman, HM Novaes, LC Ng, PG Smith, P Tharmaphornpilas, IK Yoon, A Cravioto, J Farrar, TM Nolan

Lancet Infectious Diseases | ELSEVIER SCI LTD | Published : 2019

DOI: 10.1016/S1473-3099(18)30494-8

Abstract

The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue s..

View full abstract